MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $31.93 | Prev. Close $31.56 | Circuit Range N/A |
Day Range $31.76 - $33.16 | Year Range $5.64 - $44.77 | Volume 18,643 |
Average Traded $32.81 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
08-Apr-26 | $30.88 | $31.63 | +5.40% |
07-Apr-26 | $30.26 | $30.01 | -4.49% |
06-Apr-26 | $32.95 | $31.42 | -4.96% |
02-Apr-26 | $32.21 | $33.06 | +2.23% |
01-Apr-26 | $31.21 | $32.34 | +8.25% |
31-Mar-26 | $27.86 | $29.88 | +10.57% |
30-Mar-26 | $27.87 | $27.02 | -5.49% |